Clinical Trials

Waldenstrom Macroglobulinemia

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

122 enrolled

Hodgkin Disease, Recurrence

NCT04223765 2026-01-20

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Phase 1 Recruiting

20 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04022239 2026-01-12

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Phase 1/2 Recruiting

25 enrolled

Hematopoietic and Lymphoid System Neoplasm

NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

43 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT06006117 2025-12-19

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Phase 3 Recruiting

260 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT06043713 2025-12-19

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Phase 1 Recruiting

24 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

19 enrolled

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03352765 2025-12-04

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

28 enrolled

Phase 2 Not yet recruiting

Lymphoma

NCT07259122 2025-12-02

ZBR in WM

43 enrolled

LymphoidMyeloidOther hematologic neoplasmSarcoma

Waldenstrom Macroglobulinemia

NCT02996773 2025-11-10

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Phase 1 Completed

50 enrolled

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Mycobacterium avium-intracellulare Infection, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT02315157 2025-10-15

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Phase 1 Withdrawn

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT02153580 2025-10-06

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

37 enrolled

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT07208981 2025-10-06

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Phase 2 Recruiting

169 enrolled

Phase 2 Not yet recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07206264 2025-10-03

ADAPT-MCL

45 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2 Recruiting

20 enrolled

Phase 1 Not yet recruiting

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

21 enrolled

Waldenstrom Macroglobulinemia

NCT07126678 2025-08-17

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Phase NA Recruiting

15 enrolled

Lymphoma, Follicular

NCT03834688 2025-08-11

PrE0405

Phase 2 Completed

33 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Phase 2 Active not recruiting

Hodgkin Disease

NCT03872180 2025-08-06

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

23 enrolled 15 charts

Lymphoma, Mantle-Cell

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Phase 1/2 Recruiting

53 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT04892277 2025-07-01

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Phase 1 Recruiting

25 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04515238 2025-06-10

CLL2-BZAG

42 enrolled

Phase 2 Not yet recruiting

Leukemia, B-Cell

NCT07003464 2025-06-04

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

30 enrolled

Phase EARLY_PHASE1 Completed

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03295240 2025-05-13

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

10 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT04217317 2025-05-02

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT01458366 2025-04-30

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Phase 1/2 Completed

38 enrolled 17 charts

Phase NA Not yet recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02224729 2025-04-30

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

24 enrolled 13 charts

Plasma cell

Multiple Myeloma

NCT06942507 2025-04-30

BRZ-WM

104 enrolled

Waldenstrom Macroglobulinemia

NCT01352312 2025-04-29

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1 Terminated

10 enrolled

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04587687 2025-04-24

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Phase 2 Recruiting

23 enrolled

Phase 2 Enrolling by invitation

Lymphoma, Follicular

NCT04809766 2025-04-20

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1 Terminated

9 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06931613 2025-04-17

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

20 enrolled